TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine

Acta Biochimica Polonica

Volumn 49, Issue 1, 2002, Pages 121-128

  Gloc, Ewa ^a   Warszawski, Mariusz ^a   Młynarski, Wojciech ^b   Stolarska, Małgorzata ^b   Hoser, Grazyna ^c   Skorski, Tomasz ^d   Błasiak, Janusz ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^d Temple University   (United States)

Author keywords

Amifostine, idarubicin; Comet assay; DnA damage; DNA repair; Oncogenic tyrosine kinase; TEL JAK2

Indexed keywords

MURINAE;

AMIFOSTINE; ONCOPROTEIN; TEL JAK2 FUSION PROTEIN, HUMAN; TEL JAK2 FUSION PROTEIN, MOUSE; TEL-JAK2 FUSION PROTEIN, HUMAN; TEL-JAK2 FUSION PROTEIN, MOUSE;

ANIMAL; ARTICLE; CELL CULTURE; COMET ASSAY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; KINETICS; LEUKEMIA; MOUSE;

AMIFOSTINE; ANIMALS; COMET ASSAY; DNA DAMAGE; DNA REPAIR; KINETICS; LEUKEMIA; MICE; ONCOGENE PROTEINS, FUSION; TUMOR CELLS, CULTURED;

EID: 0036048892     PISSN: 0001527X     EISSN: None     Source Type: Journal    
DOI: 10.18388/abp.2002_3828     Document Type: Article

References (30)

1. Rabbitts, T.H. (1994) Chromosomal translocations in human cancer. Nature 372, 143-149.
2. Peeters, P., Raynaud, S.D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H. & Marynen, P. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of the t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540.
3. Sawyers, C.L. (1999) Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340.
4. Ihle, J.N. (1996) Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Cancer Res. 68, 23-65.
5. Bernard, O.A., Romana, S.P., Poirel, H. & Berger, R. (1996) Molecular cytogenetics of t(12;21) (p13;q22). Leuk. Lymphoma 23, 459-456.
6. Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., Asano, S. & Kamada, N. (1999) Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13; q25). Blood 93, 1355-1363.
7. Schwaller, J., Frantsve, J., Aster, J., Williams, I.E., Tomasson, M.H., Ross, T.S., Peeters, P., Van Rompaey, L., Van Etten, R.A., Ilaria, R., Jr., Marynen, P. & Gilliland, D.G. (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17, 5321-5333.
8. Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffe, M., Mayeux, P., Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J. & Bernard, O.A. (2000) Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95, 2076-2083.
9. Ho, J.M., Beattie, B.K., Squire, J.A., Frank, D.A. & Barber, D.L. (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93, 4354-4364.
10. Nguyen, M.H., Ho, J.M., Beattie, B.K. & Barber, D.L. (2001) TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J. Biol. Chem. 276, 32704-32713.
11. Frantsve, J., Schwaller, J., Sternberg, D.W., Kutok, J. & Gilliland, D.G. (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol. 21, 3547-3557.
12. Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Fishel, R., Blasiak, J. & Skorski, T. (2002) Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis. Mol. Cell. Biol. (in press).
13. Schneider, E., Hsiang, Y. & Liu, L.F. (1990) DNA topoisomerases as anticancer drug targets. Adv. Pharmacol. 21, 149-183.
14. Platel, D., Pouna, P., Bonoron-Adele, D. & Robert, J. (1999) Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs 10, 671-676.
15. Mitchell, J.L.A., Judd, G.G., Diveley, R.R., Choe, C.Y. & Leyser, A. (1995) Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis 16, 3063-3068.
16. Milligan, J.R., Aguilera, J.A., Wu, C.C., Paglinawan, R.A., Nguyen, T.T., Wu, D. & Ward, J.F. (1997) Effect of hydroxyl radical scavenging capacity on clustering of DNA damage. Radiat. Res. 148, 325-329.
17. Ramakrishnan, N. & Catravas, G.N. (1992) N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J. Immunol. 148, 1817-1821.
18. Liu, S.C., Murley, J.S., Woloschak, G. & Grdina, D.J. (1997) Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18, 2457-2459.
19. Murley, J.S., Constantinou, A., Kamath, N.S. & Grdina, D.J. (1997) WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Proliferation 30, 283-294.
20. Douay, L., Hu, C., Giarratana, M.C., Bouchet, S., Conlon, J., Capizzi, R.L. & Gorin, N.C. (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging. Blood 86, 2849-2855.
21. Valeriote, F. & Tolen, S. (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 42, 4330-4331.
22. Huang, X.K., Gao, X.Z., Burke, P., Raza, A. & Preisler, H.D. (1997) The effects of amifostine on the clonogenic proliferation in vitro of myelodysplastic and acute and chronic myelogenous leukemia cells. ASCO Proc. 16, 1848a.
23. Singh, N.P., McCoy, T., Tice, R.R. & Schneider, E.L. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175, 184-192.
24. Klaude, M., Eriksson, S., Nygren, J. & Ahnstrom, G. (1996) The comet assay: Mechanisms and technical considerations. Mutat. Res. 12, 89-96.
25. Błasiak, J. & Kowalik, J. (2001) Protective action of vitamin C against DNA damage induced by selenium-cisplatin conjugate. Acta Biochim. Polon. 48, 233-240.
26. Ashby, J.A., Tinwell, H., Lefevre, P.A. & Brown, M.A. (1995) The single cell gel electrophoresis assay for induced DNA damage (comet assay): Measurement of tail lenght and moment. Mutagenesis 10, 85-90.
27. Kurbacher, C.M. & Mallmann, P.K. (1998) Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721). Anticancer Res. 18, 2203-2210.
28. Pierelli, L., Scambia, G., Fattorossi, A., Bonanno, G., Battaglia, A., Perillo, A., Menichella, G., Panici, P.B., Leone, G. & Mancuso, S. (1998) In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: Haematoprotection acts as a drug-specific progenitor rescue. Br. J. Cancer 78, 1024-1029.
29. Buschini, A., Anceschi, E., Carlo-Stella, C., Regazzi, E., Rizzoli, V., Poli, P. & Rossi, C. (2000) Amifostine (WR-2721) selective protection against melphalan genotoxicity. Leukemia 14, 1642-1651.
30. Newton, G.L., Aguilera, J.A., Ward, J.F. & Fahey, R.C. (1996) Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei. Radiat. Res. 146, 289-305.